Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic Alpha Clinic Contact Trial Sponsor Disease Indication Clinical Trial Namesort descending Status of Enrollment Learn More
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Eye - Retinopathy Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy Recruiting
UCSF
Romobia Hutchinson
415-476-9326
romobia.hutchinson@ucsf.edu
UCSF Blood Disorder - Alpha Thalassemia Major In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Recruiting
UCLA
& UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu
UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) Active, not recruiting
City of Hope
Elizabeth Budde, MD
626-218-2405
Kite Pharma Cancer - Lymphoma A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma Recruiting
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting
UCSF
Julie DeCaris
510-428-3885 ext 2739
jdecaris@mail.cho.org
Seattle Children's Hospital Foundation Cancer - Leukemia A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Recruiting
UC Davis Orca Biosystems, Inc. Hematologic Malignancies A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) Recruiting
UCSF
Julie DeCaris
510-428-3885. ext.2739
jdecaris@mail.cho.org
Bioverativ Therapeutics, Inc Sickle Cell Disease A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis B-Cell Leukemia A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
UCI
& UC Davis
UCI Stem Cell Clinic: Roy Fujitani
949-824-3990
stemcell@uci.edu
Humacyte Kidney failure A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
BrainStorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS Recruiting
UC Davis
& UCSD & UCSF
Deborah Stewart
916-703-9118
distewart@ucdavis.edu
UC Davis HIV & Lyimphoma A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells Recruiting
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Teresa Kim
626-218-0263
teresakim@coh.org
City of Hope Sickle Cell Disease A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Pluristem Ltd. Critical Limb Ischemia (CLI) A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ReNeuron Limited Stroke A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) Recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus Recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Kite Pharma Advanced Cancer A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 5396
CBascon@mail.cho.org
bluebird bio Sickle Cell Disease A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Muscle - Duchenne Muscular Dystrophy A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) Recruiting
City of Hope
Myo Htut, MD
626-218-2405
mhtut@coh.org
Janssen Research & Development, LLC. Cancer - Myeloma A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) Recruiting
UCSD
& City of Hope
UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
UCSF
& UCLA
Marci Moriarty, BSN, RN
510-428-3885 ext 5396
mmoriarty@mail.cho.org
Bruck Habtemariam
310-794-0242
bhabtemariam@mednet.ucla.edu
Sangamo Therapeutics Blood Disorder - Beta-Thalassemia A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) Recruiting
City of Hope
Lucy Ghoda
626-218-3605
lghoda@coh.org
City of Hope Neurodegenerative Disorder Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies Recruiting
UCLA
Scott Nowicki, MD, PhD
Ignacio Baselga Carretero, PhD
310-206-2090
IBaselga@mednet.ucla.edu
UCLA Cancer - Solid Tumors Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies Recruiting
UCSF
Carol Fraser-Brown
415-476-2188
carol.fraser-browne@ucsf.edu
Stanford University Severe Combined Innunodeficiency (SCID) AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Recruiting
UCI
& UC Davis
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
UC Davis: Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Humacyte Kidney Failure An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) Active, not recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
City of Hope
Cara Nolan
626-218-3241
canolan@coh.org
Juno Therapeutics Cancer - Lymphoma An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting
City of Hope
Elizabeth Budde, MD, PhD
626-218-2405
ebudde@coh.org
City of Hope Cancer - Lymphoma Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children's Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
​newing@coh.org
Sangamo Therapeutics Hemophilia B Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B Recruiting
UCI
& UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Tongue Dysphagia Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia Recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) No longer active
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
UC Davis
Jane McCluskepy
916-703-9302
jmccluskey@ucdavis.edu
Medeor Therapuetics Kidney Transplant Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants Recruiting
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens Recruiting
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting

Pages

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News